Outcome analysis of assisted reproduction technology in 37 patients with malignant tumors
10.3760/cma.j.cn101441-20191025-00484
- VernacularTitle:37例女性恶性肿瘤治疗后辅助生殖技术助孕结局分析
- Author:
Rongshan LI
1
;
Xiaojing CHEN
1
;
Suqin ZHU
1
;
Peiyang LIN
1
;
Wenwen JIANG
1
;
Xuefen CAI
1
;
Beihong ZHENG
1
Author Information
1. 福建省妇幼保健院生殖中心，福建医科大学附属医院；福建省生殖医学中心，福州 350001
- Publication Type:Journal Article
- Keywords:
Fertility needs;
Reproductive technology, assisted;
Women of childbearing age;
Malignant tumor
- From:
Chinese Journal of Reproduction and Contraception
2020;40(6):481-486
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the effectiveness and safety of assisted reproductive technology in the fertility needs of female patients with malignant tumors.Methods:A total of 37 female malignant tumor patients (case group) who underwent adjuvant reproductive therapy in Fujian Provincial Maternity and Children's Hospital from 2013 to 2018 were enrolled. Totally 74 non-tumor patients were matched as control group according to age and egg retrieval time using a 1：2 matching method. By analyzing the demographic data and the first pregnancy data, the clinical pregnancy rate and the implantation rate of the first transplant cycle were calculated, and the pregnancy outcomes of case group and control group were evaluated.Results:There was no significant difference in the demographic data between the two groups. There was no significant difference in the basic follicle-stimulating hormone (FSH) level, basic luteinizing hormone (LH) level, estradiol and progesterone levels on human chorionic gonadotropin (hCG) injection day during the first treatment period ( P>0.05). The differences of total amount of gonadotropin (Gn) used [(1 984.93±756.79) IU vs. (2 610.59±988.52) IU, P=0.001], duration of Gn used [(9.68±2.57) d vs. (11.64±2.47) d, P<0.001], high-quality embryo rate (49.56% vs. 58.94%, P=0.016) and the number of embryos transferred (1.4±0.5 vs. 1.8±0.4， P=0.001) between case group and control group were statistically significant. There was no significant difference in the clinical pregnancy rate and the implantation rate between the two groups ( P>0.05). Cumulative pregnancy rate, cumulative live birth rate, the number of egg retrieval cycles per live birth, the number of transplant cycles, the number of embryos, and the number of high-quality embryos were not statistically significant ( P>0.05). Tumor patients receiving assisted reproductive assistance have not been found so far recurrence or new tumor. Conclusion:Compared with control group, the pregnancy outcomes after assisted reproductive technology in female malignant tumor patients were not significantly different. Assisted reproductive technology can fulfill the fertility needs of female malignant tumors after surgery and is safety.
